Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenylbutanoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 4/20 | 0.95 |
| ▸ | HDAC3 known ✓ | O15379 | 3/20 | 0.95 |
| ▸ | HDAC2 known ✓ | Q92769 | 3/20 | 0.95 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 3/20 | 0.95 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 3/20 | 0.95 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 3/20 | 0.95 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.95 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 2/20 | 0.95 |
| ▸ | HDAC10 known ✓ | Q969S8 | 2/20 | 0.95 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 2/20 | 0.95 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 2/20 | 0.95 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.80 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylbutanoic Acid SCHEMBL28684695 | 1.00 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL1021513 | 0.98 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL21219015 | 0.98 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL1716 | 0.98 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL29272534 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL31228551 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL7723613 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL726614 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL29272542 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| Phenylbutanoic Acid SCHEMBL27900207 | 0.95 | HDAC1 (0.95) | HDAC1HDAC3HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4272502-A | Process for preparing gaseous hydrogen chloride from dilute aqueous hydrochloric acid | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) | 1981-06-09 | — | — | US | claimed |
| CN-110337442-B | Novel glucose derivatives as inhibitors of sodium-dependent glucose transporter type 2 | 东亚ST株式会社 | 2023-05-12 | — | — | CN | disclosed |
| CN-110337442-A | Novel grape sugar derivatives as 2 type sodium dependent glucose transporter inhibitors | 东亚ST株式会社 | 2019-10-15 | — | — | CN | disclosed |
| CN-107188808-A | A kind of synthetic method of the phenylbutyric acid hydrochloride of 4 amino 3 | 江苏斯威森生物医药工程研究中心有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-107188808-A | A kind of synthetic method of the phenylbutyric acid hydrochloride of 4 amino 3 | 江苏斯威森生物医药工程研究中心有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-107188808-A | A kind of synthetic method of the phenylbutyric acid hydrochloride of 4 amino 3 | 江苏斯威森生物医药工程研究中心有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-206417438-U | A kind of hydrochloric acid tank for being used to prepare the phenylbutyric acid hydrochloride of 4 amino 3 | 浙江邦成化工有限公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-206417438-U | A kind of hydrochloric acid tank for being used to prepare the phenylbutyric acid hydrochloride of 4 amino 3 | 浙江邦成化工有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-1737819-B1 | AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE | DSM IP ASSETS BV (NL) | 2010-12-22 | — | — | EP | disclosed |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| CN-1325843-A | Synthesis of 2-(s)-amino-4-phenyl (substituted aryl) butanoic acid and its ester (hydrochloride) | CHENGDU ORGANIC CHEM INST (CN) | 2001-12-12 | — | — | CN | disclosed |
| CN-1056844-C | Dioxide pyrrolo-pyrrolo derivatives | HOFFMANN LA ROCHE (CH) | 2000-09-27 | — | — | CN | disclosed |
| CN-1136567-A | Dioxide pyrrolo-pyrrolo derivatives | HOFFMANN LA ROCHE (CH) | 1996-11-27 | — | — | CN | disclosed |
| US-5235072-A | 2-OXABICYCLO(2,2,1)HEPTANE DERIVATIVES AND PHARMACEUTICAL | SCHERING AKTIENGSELLSCHAFT (DE) | 1993-08-10 | — | — | US | disclosed |
| EP-0105919-B1 | 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1987-07-08 | — | — | EP | disclosed |
| EP-0105919-A1 | 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES. | CIBA GEIGY AG (CH) | 1984-04-25 | — | — | EP | disclosed |
| WO-1983003828-A1 | 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1983-11-10 | — | — | WO | disclosed |
| US-4272502-A | Process for preparing gaseous hydrogen chloride from dilute aqueous hydrochloric acid | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) | 1981-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | HDAC1 2281/4885HDAC3 597/4885HDAC2 779/4885 |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | HDAC1 1067/4885HDAC3 1862/4885HDAC2 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.